-+ 0.00%
-+ 0.00%
-+ 0.00%
Gates Foundation extends funding for AN2 Therapeutics-GSK TB drug research collaboration
Share
Listen to the news
Gates Foundation extends funding for AN2 Therapeutics-GSK TB drug research collaboration
  • AN2 Therapeutics received extended Gates Foundation funding for its tuberculosis R&D collaboration with GSK.
  • Funding supports development of boron-based leucyl-tRNA synthetase inhibitors as potential new TB treatments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260928957267) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending